Derzeit nicht verfügbar
Handgeprüfte Gebrauchtware
Bis zu 50 % günstiger als neu
Der Umwelt zuliebe
Drug Delivery Challenges and Novel Therapeutic Approaches for Retinal Diseases
(Gebundene Ausgabe, Englisch)
Keine Bewertungen vorhanden
Optischer Zustand
Beschreibung
This book reviews the current state of ocular drug therapy and future therapeutic opportunities for a wide variety of conditions, including Age-related Macular Degeneration, Diabetic Retinopathy and Macular Edema, Glaucoma, and Inherited Retinal Diseases. Retinal diseases are major contributors to moderate or severe vision impairment in adults aged 50 years and older. The respective patient Dieses Produkt haben wir gerade leider nicht auf Lager.
Handgeprüfte Gebrauchtware
Bis zu 50 % günstiger als neu
Der Umwelt zuliebe
Technische Daten
Erscheinungsdatum
24.09.2020
Sprache
Englisch
EAN
9783030566180
Herausgeber
Springer International Publishing
Serien- oder Bandtitel
Topics in Medicinal Chemistry
Sonderedition
Nein
Seitenanzahl
272
Auflage
1st edition 2020
Einbandart
Gebundene Ausgabe
Autorenporträt
Christopher L. Cioffi is an Assistant Professor of Medicinal Chemistry in the Department of Basic and Clinical Sciences and the Department of Pharmaceutical Sciences at Albany College of Pharmacy and Health Sciences. Christopher received his doctorate in Organic Chemistry from Rensselaer Polytechnic Institute in 2000. He subsequently conducted a 16-year career as a medicinal chemist at Albany Molecular Research, Inc. where he led numerous medicinal chemistry teams and made significant drug design contributions to programs that advanced drug candidates into pre-clinical development and clinical trials. His work has spanned several therapeutic areas that include cardiovascular, gastrointestinal, CNS, and ophthalmic indications. Notably, Christopher has contributed to the discovery of Eli Lilly’s cholesteryl ester transfer protein inhibitor evacetrapib, which progressed to Phase III clinical trials for dyslipidemia. Additionally, he has co-discovered the 5-HT3 partial agonist SMP-100 (SciMount Therapeutics) to be studied for efficacy against IBS-D and the retinol binding protein 4 antagonist tinlarebant (Belite Bio) for the treatment of Stargardt disease. Tinlarebant has completed Phase I clinical trials and Phase II trials with Stargardt disease patients are expected to commence in 2020. SMP-100 is currently undergoing Phase I clinical trials. Christopher joined Albany College of Pharmacy and Health Sciences in 2016 and is engaged drug discovery projects focused in the areas of atrophic age-related macular degeneration and chronic pain.
Schlagwörter
Macular Degeneration, Stargardt Disease, Glaucoma, Diabetic Retinopathy, Diabetic Macular Edema, Ocular Pharmacokinetics, Retinal Diseases, Current Ocular Drug Discovery, gene therapy
Thema-Inhalt
PNB - Medizinische Chemie, Pharmazeutische Chemie
MJQ - Augenheilkunde
MFN - Genetik, Medizin
Höhe
235 mm
Breite
15.5 cm
Hersteller: Springer, Europaplatz 3, Heidelberg, Deutschland, 69115, ProductSafety@springernature.com, Springer Nature Customer Service Center GmbH
-.-
Leider noch keine Bewertungen
Leider noch keine Bewertungen
Sicher bei rebuy kaufen
Schreib die erste Bewertung für dieses Produkt!
Wenn du eine Bewertung für dieses Produkt schreibst, hilfst du allen Kund:innen, die noch überlegen, ob sie das Produkt kaufen wollen. Vielen Dank, dass du mitmachst!
Sicher bei rebuy kaufen